Canagliflozin-associated diabetic ketoacidosis: a case report

Canagliflozin is a novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor approved for the management of diabetes. We report the presentation and management of two cases of canagliflozin associated diabetic ketoacidosis (DKA) and discuss the mechanism of canagliflozin associated DKA. Patient 1, a 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Peter R., Bonney, Caitlin, Blohm, Eike, Boyer, Edward W., Babu, Kavita M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029867/
https://www.ncbi.nlm.nih.gov/pubmed/29978156
http://dx.doi.org/10.1080/24734306.2017.1331604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029867/
https://www.ncbi.nlm.nih.gov/pubmed/29978156
http://dx.doi.org/10.1080/24734306.2017.1331604

Ejemplares similares